At its meeting this week, the PBAC will consider the 'discount rate' but as the national expert advisory body on medicines is not lawfully allowed to provide advice on treatments in the National Medical Stockpile or many of the new therapeutic interventions emerging from company pipelines. What is the real problem? …
This legal quirk of history is a much bigger problem than the 'discount rate'
July 8, 2022 Latest NewsBioPharmaCommentNews of the Day
Latest Video
Georgia Forrest
New Stories
-
The Dispatched Podcast 'Week in Review' - 20 February
February 20, 2026 - - Podcast -
PhRMA launches new campaign against the backdrop of a more assertive U.S.
February 19, 2026 - - Latest News -
Why does anyone accept a review outcome that simply affirms a settled order
February 19, 2026 - - Latest News -
Wesfarmers Health emerges as growth engine after delivering strong first half
February 19, 2026 - - Australian Biotech -
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Australian Biotech -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Australian Biotech